ImmunOnsia Makes KOSDAQ Debut... "Growth Momentum Expected This Year with Technology Out-Licensing"

Up 116% Intraday on First Day of Listing

Kim Heungtae, CEO of ImmunOnsia, wearing a red jacket, and Jo Wookje, CEO of Yuhan Corporation (to the right of Kim Heungtae), are taking a commemorative photo with employees on the 19th at the Korea Exchange in Yeongdeungpo-gu, Seoul. Photo by ImmunOnsia

ImmunOnsia, a company specializing in the development of immuno-oncology drugs under Yuhan Corporation, was listed on the KOSDAQ market on this day.

As of 10:35 a.m. on the 19th, ImmunOnsia was trading at 7,810 won, up 4,210 won (116.94%) from its offering price of 3,600 won.

During the public subscription held on the 7th and 8th, the competition ratio reached 913 to 1, and approximately 3.7563 trillion won in subscription deposits was collected. In the earlier demand forecast for institutional investors, the competition ratio was 897.45 to 1, achieving strong results, and the offering price was set at the upper end of the desired band (3,000 to 3,600 won).

Founded in 2016, ImmunOnsia is a subsidiary of Yuhan Corporation and is developing immune checkpoint inhibitors targeting T cells and macrophages. 'IMC-002' was licensed out to 3D Medicines in China in 2021, granting exclusive rights for the Greater China region. The company is aiming for an additional global technology out-licensing in 2026.

Another pipeline, 'IMC-001', is expected to complete its clinical study report (CSR) next month. The company is targeting orphan drug designation (ODD) approval, global technology out-licensing in 2027, and domestic commercialization in 2029. In addition, ImmunOnsia is expanding the development of a bispecific antibody platform based on a monoclonal antibody that has demonstrated efficacy in clinical trials. Ultimately, the company aims to secure a revenue base through technology out-licensing at the early preclinical stage and domestic commercialization.

Kim Heungtae, CEO, stated, "Starting with global technology out-licensing in 2026, we will become a company that creates meaningful momentum every year," adding, "This year, we plan to present promising clinical results at ASCO (American Society of Clinical Oncology)."